Explore the vast range of titles available.

The COVID-19 pandemic has exacerbated prevalence of alcohol use and violence, including gender-based violence (GBV); however, little is understood about the pandemic’s impact on the relationship between the two. Data were collected from January 2021-April 2023 with adults who drink alcohol (N = 565) in the San Francisco Bay Area. Questions assessed prevalence of heavy alcohol use (≥4 drinks on one occasion ≥4 times a month) in the past 3 months and violence/GBV exposure before and during the pandemic. Logistic regression examined associations between violence and alcohol use. Overall, participants reported heavy alcohol use (73.7%), strong desire for alcohol (53.3%), ever experiencing violence (71.6%), and GBV (20.5%). During the pandemic, participants reported experiencing violence (26.1%), more violence than usual (13.8%), GBV (8.9%), and drinking more alcohol (43.7%). People who experienced violence during the pandemic had significantly greater odds of reporting heavy alcohol use (OR = 1.76, p = 0.05) and drinking more during the pandemic than usual (OR = 2.04, p<0.01). Those who reported experiencing more violence during the pandemic than usual had significantly greater odds of reporting heavy alcohol use (OR = 2.32, p = 0.04) and drinking more during the pandemic (OR = 2.23, p<0.01). People who experienced GBV during the pandemic reported a significantly stronger desire for alcohol (OR = 2.44; p = 0.02) than those not exposed. Alcohol-related harms increased over the COVID-19 pandemic, including increased violence/GBV, alcohol use, and an elevated desire to use alcohol among those who experienced violence during the pandemic. Future pandemic preparedness efforts must prioritize violence prevention strategies and adapt alcohol harm reduction, recovery, and treatment programs to pandemic conditions.

Background Rates of cocaine use disorder (CUD) among men who have sex with men (MSM) are high and rising. Among MSM, cocaine use is associated with negative socioeconomic, medical, and psychological outcomes. There are no FDA-approved pharmacotherapy options to treat CUD, and psychosocial interventions demonstrate limited efficacy. While there have been numerous trials evaluating possible medications for CUD, there is a scarcity of qualitative data on the barriers and facilitators of medication-assisted treatment. Methods Semi-structured interviews were conducted with 16 participants enrolled in a phase II randomized control trial evaluating extended-release lorcaserin among MSM with CUD. Participants were asked about their motivations for enrolling in the study, attitudes towards taking a medication for CUD, barriers and facilitators of study pill adherence, and their general study experience. Interviews were analyzed using an inductive and exploratory approach to thematic analysis. Results Participants were highly motivated to reduce cocaine use and viewed pharmacotherapy as a viable and desirable treatment option. Pharmacotherapy was seen as having fewer access and adherence structural barriers compared to existing psychosocial therapies. Medication reminders facilitated pill taking, while side effects, travel, and active substance use presented barriers to study pill adherence. Disclosure of study participation within social networks was variable pointing to anticipated substance use and treatment stigma. Conclusions Our study highlights important factors affecting the acceptability and uptake of medication-assisted treatment for CUD among a diverse sample of MSM. These findings can help guide the development and implementation of future pharmacotherapy options for CUD and other substance use disorders in this key population.